

BEXIMCO PHARMACEUTICALS LIMITED

17, DHANMONDI, ROAD NO. 2,
DHAKA-1205

PRICE SENSITIVE INFORMATION

This is for information of all concerned that the Board of Directors of the Company in their meeting held on 25 October, 2018 at 3.30 p.m. has approved the audited Financial Statements for the year ended 30 June, 2018 and took the following decisions:

1. Recommended Dividend : 12.5% Cash Dividend.
 2. Record date : 26 November, 2018.
 3. Date & Time of 42nd AGM : 22 December, 2018 at 10.30 A.M.
 4. Venue of AGM : Beximco Industrial Park, Sarabo, Kashimpur, Gazipur.
5. The Board of Directors in their said meeting also decided to hold an Extra-Ordinary General Meeting (EGM) to pass Special Resolutions to amend certain Clauses of Memorandum of Association and Articles of Association of the Company and took the following decisions **with respect to the EGM**:

- Record date : 26 November, 2018.
Date & Time : 22 December, 2018 at 10.00 A.M.
Venue : Beximco Industrial Park, Sarabo, Kashimpur, Gazipur.

Comparative Financial Disclosures:

Beximco Pharmaceuticals Limited (Stand-alone)

Particulars	Year ended 30 June, 2018	Year ended 30 June, 2017
Net Profit after Tax	Tk.2,558,971,263	Tk.2,226,695,124
Earnings Per Share (EPS)	Tk.6.31	Tk.5.49
Net Asset Value (NAV)	Tk.27,104,389,931	Tk.25,072,425,900
Net Asset Value per share (NAVPS)	Tk.66.83	Tk.61.82
Net Operating Cash Flow Per Share (NOCFPS)	Tk.4.56	Tk.5.89*

* Restated

Beximco Pharmaceuticals Limited and its Subsidiary (Consolidated)

Particulars	Year ended 30 June, 2018
Net Profit after Tax	Tk.2,532,654,301
Earnings Per Share (EPS)	Tk.6.25
Net Asset Value (NAV)	Tk.27,081,962,616
Net Asset Value per share (NAVPS)	Tk.66.78
Net Operating Cash Flow Per Share (NOCFPS)	Tk.4.49

By order of the Board,

Sd/-

(MOHAMMAD ASAD ULLAH, FCS)

EXECUTIVE DIRECTOR & COMPANY SECRETARY

Dated: 25 October, 2018